Tag:
Regeneron
Latest Headlines
Latest Headlines
The biggest R&D spenders in biotech
Last year the top 10 biotechs in the world spent $10.2 billion on R&D, up a whopping 13% over their $8.9 billion track record in 2010.
FDA panel nixes Regeneron's Arcalyst for gout
Regeneron may not be able to aim Aracalyst at the lucrative gout market.
FDA advisers snub Regeneron drug for gout
An FDA advisory committee rejected Arcalyst in an 11-0 vote against approval as experts harbored concerns about the lack of safety data and the limited time period of 16 weeks patients took the drug in studies.
FDA notes cancer cases linked to Regeneron gout drug
The FDA staff review questioned whether the risks of the treatment overwhelm the benefits of the drug in combating gout flare-ups.
Sanofi colorectal cancer contender Zaltrap suffers a PhIII trial setback
Sanofi and Regeneron's opened their update on the cancer drug Zaltrap (aflibercept) on a sweet note: The FDA has granted a priority review of their NDA for colorectal cancer.
How do the 12 priciest drugs in the U.S. stack up?
Last week, Vertex Pharmaceuticals ( $VRTX ) got FDA approval for Kalydeco, the first cystic fibrosis drug to address the disease's cause, rather than just its symptoms. The price tag: $294,000. But as
Genentech pursues sustained-delivery version of blockbuster eye drug Lucentis
Ah, progress. Genentech has overcome an initial hurtle in its push to develop a sustained-delivery version of Lucentis , the company's blockbuster drug for age-related macular degeneration. The...
Regeneron to pay Roche royalties on Eylea sales
Genentech's spat with Regeneron Pharmaceuticals ( $REGN ) is partly settled. The two companies have been fighting over Regeneron's new injectable eye drug Eylea , which is the first challenger to
Eylea may beat Lucentis on price, but what of Avastin?
The Lucentis-versus-Avastin debate just got a bit more complicated. Regeneron Pharmaceuticals ($REGN) won FDA approval for its macular degeneration drug Eylea, putting it in competition with Roche's
Sanofi drug packs anti-cholesterol punch in Ph2 trials
French drug giant Sanofi ($SNY) and U.S. biotech Regeneron ($REGN) have provided some impressive evidence that their antibody, dubbed REGN727, helps dramatically reduce levels of LDL cholesterol in
